Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Patent
1994-07-11
1998-11-03
Achutamurthy, Ponnathapura
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
530351, A61K 4505, A61K 3820
Patent
active
058304525
ABSTRACT:
The present application relates to a method for enhancing the therapeutic index of a compound that is useful to treat tumors. More specifically, the present invention relates to a method for administering IL-2 to a tumor patient to maximize the therapeutic efficacy and minimize the toxicity.
REFERENCES:
patent: 4401756 (1983-08-01), Gillis
patent: 4518584 (1985-05-01), Mark et al.
patent: 4530787 (1985-07-01), Shaked et al.
patent: 4569790 (1986-02-01), Koths et al.
patent: 4572798 (1986-02-01), Koths et al.
patent: 4604377 (1986-08-01), Fernandes et al.
patent: 4624661 (1986-11-01), Arimond
patent: 4637834 (1987-01-01), Thurow
patent: 4656132 (1987-04-01), Ben-Bassat et al.
patent: 4738927 (1988-04-01), Taniguchi et al.
patent: 4748234 (1988-05-01), Dorin et al.
patent: 4752585 (1988-06-01), Koths et al.
patent: 4766106 (1988-08-01), Katre et al.
patent: 4816440 (1989-03-01), Thompson
patent: 4863726 (1989-09-01), Stevens et al.
patent: 4885164 (1989-12-01), Thurow
patent: 4894226 (1990-01-01), Aldwin et al.
patent: 4902501 (1990-02-01), Bandi et al.
patent: 4902502 (1990-02-01), Nitecki et al.
patent: 4908433 (1990-03-01), Mertelsmann et al.
patent: 4908434 (1990-03-01), Mertelsmann et al.
patent: 4925919 (1990-05-01), Mertelsmann et al.
patent: 4992271 (1991-02-01), Fernandes et al.
patent: 5037644 (1991-08-01), Shaked et al.
patent: 5078997 (1992-01-01), Hora et al.
patent: 5102872 (1992-04-01), Singh et al.
Bauer et al., "Protein Drug Delivery by Programmed Pump Unfusion to Enhance the Therapeutic Index and to Aid in the Design of Next-Generation Drugs: Interleukin-2," in Therapeutic Proteins-Pharmacokinetics and Pharmacodynamics, Kung et al. (eds.), W.H. Freeman and Company, New York, pp. 239-253 (1993).
Bauer, et al., "Enhacement of Cytokine (IL-2.sub.- Therapeutic Ratio By Controlling Plasma Clearance Profiles" FASEB J., 4(7), #1733 (A 1991).
Katre et al., "Chemical Modification of Interleukin 2 with Polymers: A Potent Drug-delivery System," In Marshak, D., and Liu, D., eds., Therapeutic Peptides and Proteins, Cold Spring Harbor Laboratory, Long Island, NY pp. 173-177 (1989).
Stoter et al., "Metastatic renal cell cancer treated with low-dose interelukin-2. A phase-II multicentre study," Cancer Treatment Reviews 16(A):111-113 (1989).
West et al., "Constant-Infusion Recombinant Interleukin-2 In Adoptive Immunotherapy of Advanced Cancer," The New England Journal of Medicine, 316(15):898-905 (Apr. 9, 1987).
Zimmerman et al. (1989, Dec. 1), Cancer Res. 49:6521-6528.
Vaage et al. (1987). Int. J. Cancer 39:530-533.
Lotze et al.(1986). Cancer 58:2764-2772.
Krigel et al.(1988, Jul. 1). Cancer Res. 48:3875-3881.
Talmadge et al.(1987) Cancer Res. 47:5725-5732.
Winkelhake et al.(1987) Cancer Res. 47:3948-3953.
Kohler et al.(1989) Cancer Investigation 7(3):213-223.
Hadden(1988) Cancer Detection & Prevention 12:537-552.
Abuchowski, et al. Cancer Biochem.Biophys. 7:175 (1984), "Cancer therapy with chemically modified enzymes I. Antitumor properties of polyethylene glycol-asparaginase conjugates".
Beauchamp, et al., Anal.Biochem. 131:25 (1983), "A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and .alpha..sub.2 macroglobulin".
Davis, et al., Biomedical Polymers, Academic Press, New York, pp. 441-451 (1980).
Devos, Nucl.Acids Res. 11:4307 (1983), "Moleccular cloning of human interleukin 2 cDNA and its expression in E.coli".
Donohue, et al., Cancer Res. 44:1380 (1983), "In vivo administration of purified Jurkat-derived interleukin 2 in mice".
Donohue, et al., J.Immunol. 130:2203 (1983), "The fate of interleukin-2 after in vivo administration".
Gillis, et al., J.Exp.Med. 152:1709 (1980), "Biochemical and biological characterization of lymphocyte regulatory molecules".
Gillis, et al. J.Immuol. 124:1954 (1980), "Biochemical characterization of lymphocyte regulatory molecules".
Katre, et al., Proc.Natl.Acad.Sci. (USA) 84:1487 (1987), "Chemica;1 modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model".
Knauf, et al., J.Biol.Chem. 263:15064 (1988), "Relationship of effective molecular size to systemic clearance in rat of recombinant interleukin-2 chemically modified with water-soluble polymers".
Matory, et al., J.Biol.Resp.Mod. 4:377 (1985), "Toxicity of recombinant human interleukin-2 in rats following intravenous infusion".
Mochizuki, et al., J.Immunol.Meth. 39:185 (1985), "Biochemical separation of interleukin-2".
Morgan, et al., Science 193:1007 (1976), "Selective growth of T lymphocytes from normal human bone marrow cells".
Morikawa, et al, Cancer Res. 47:37 (1987), "Enhancement of therapeutic effects of recombinant interleukin 2 on a transplantable rat fibrosarcoma by the use of a sustained relase vehicle, pluonic gel".
Nishimura, et al., Cancer Immunol.Immunother. 21:12 (1986), "Augmentation of the thrapeutic efficacy of adoptive tumor immunotherapy by in vivo administration of a slowly released recombinant interleukin 2".
Nishimura, et al., J.Immunol.Meth. 91:21 (1986), "Augmentation of the efficacy of adoptive immunotherapy with lymphokine-activated killer (LAK) cells".
Rosenberg, et al., J.Exp.Med. 161:1169 (1985), "Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high dose recombinant interleukin-2".
Taniguchi, et al., Nature 302:305 (1983), "Structure and expression of a cloned cDNA for human interleukin-2".
Watson, et al., J.Exp.Med. 150:849 (1979), "Biochemical and biological characterization of lymphocyte regulatory molecules".
Welte, et al., J.Exp.Med. 156:454 (1982), "Purification of human interleukin 2 to appartent homogeniety and its molecular heterogeneity".
Bauer Robert J.
Winkelhake Jeffrey L.
Young John D.
Zimmerman Robert
Achutamurthy Ponnathapura
Blackburn Robert P.
Chiron Corporation
McGarrigle Philip L.
Pochopien Donald
LandOfFree
Method for enhancing the anti-tumor therapeutic index of interle does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for enhancing the anti-tumor therapeutic index of interle, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for enhancing the anti-tumor therapeutic index of interle will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-686620